Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells

Experimental Cell Research

Volumn 293, Issue 2, 2004, Pages 283-291

  Liang, Xing Jie ^a   Yin, Jun Jie ^b   Zhou, Jien Wei ^c   Wang, Paul C ^c   Taylor, Barbara ^a   Cardarelli, Carol ^a   Kozar, Michael ^d   Forte, Raynard ^d   Aszalos, Adorjan ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c HOWARD UNIVERSITY   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Cisplatin resistance; Fluorescence polarization; Heptadecanoic acid; Human epidermal carcinoma KB cells; Membrane potential; Plasma membrane fluidity

Indexed keywords

CISPLATIN; HEPTADECANOIC ACID; POTASSIUM CHANNEL;

ARTICLE; CANCER RESISTANCE; CELL MEMBRANE FLUIDITY; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; HUMAN; HUMAN CELL; LIPID COMPOSITION; PRIORITY JOURNAL;

EID: 9144271121     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2003.10.012     Document Type: Article

References (31)

1. Chen Z.S., Mutoh M., Sumizawa T., Furukawa T., Haraguchi M., Tani A., Saijo N., Kondo T., Akiyama S.I. An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. Exp. Cell Res. 240:1998;312-320.
2. Bungo M., Fujiwara Y., Kasahara K., Nakagawara K., Ohe Y., Sasaki Y., Irino S., Saijo N. Decreased accumulation as a mechanism of resistance to cis-diamminodichloro platinum (II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res. 50:1990;2549-2553.
3. Burger H., Nooter K., Boersma A.W., Kortland C.J., Stoter G. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumor cell lines. Br. J. Cancer. 77:1998;1562-1567.
4. Kigawa J., Sato S., Shimada M., Takahasi M., Itamochi H., Kanamori Y., Terakwa N. p53 gene status and chemosensitivity in ovarian cancer. Hum. Cell. 14:2001;165-171.
5. Adachi S., Obaya A.J., Han Z., Ramos-Desimone N., Wyche J.H., Sedivy J.M. c-Myc is necessary for DNA damage-induced apoptosis in the G phase of cell cycle. Mol. Cell. Biol. 21:2001;4929-4937.
6. Kuwahara D., Tsutsumi K., Kobayashi T., Hyoudou M., Koizuka I. Inhibition of caspase-9 activity in cisplatin-resistant head and neck squamous cell carcinoma. Nippon Jibi Inkoka Gakkai Kaiho. 105:2002;152-157.
7. Lin-Chao S., Chao C.C. Reduced inhibition of DNA synthesis and G(2) arrest during the cell cycle of resistant HeLa cells in response to cis-diamminedichloroplatinum. J. Biomed. Sci. 1:1994;131-138.
8. Spellman G., Staffhorst R.W., Versluis K., Reedijk J., de Kruijff B. Cisplatin complexes with phosphatidylserine in membranes. Biochemistry. 36:1997;10545-10550.
9. Briz O., Serrano M.A., Macias R.I.R., Marin J.J.G. Overcoming cisplatin resistance in vitro by a free and liposome-encapsulated bile acid derivative: Bamet-R2. Int. J. Cancer. 88:2000;287-292.
10. Akiyama S., Fojo A., Hanover J.A., Pastan I., Gottesman M.M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol. Genet. 11:1985;117-126.
11. Shen D.-W., Akiyama S., Schoenlein P., Pastan I., Gottesman M.M. Characterization of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br. J. Cancer. 71:1995;676-683.
12. Csermely P., Balint E., Grimley P.M., Aszalos A. Protein kinase C is involved in the early signal of interferon-α but not of interferon-γ in U937 cells. J. Interferon Res. 10:1990;605-611.
13. Collins I.M., Scott R.B. Plasma membrane fluidity gradients of human peripheral blood leukocytes. J. Cell. Physiol. 144:1990;42-51.
14. Aszalos A., Yang G.C., Gottesman M.M. Depolymerization of microtubules increases the motional freedom of molecular probes in cellular plasma membranes. J. Cell Biol. 100:1985;1357-1363.
15. Yin J.J., Smith M.J., Epply R.M., Troy A.L., Page S.W., Sphon J.A. Effects of furnorisin B1 and (hydrolyzed) fumonisin backbone API on membranes: a spin-label study. Arch. Biochem. Biophys. 335:1996;13-22.
16. Schlegel R.A., Stevens M., Lurnley-Sapanski K., Williamson P. Altered lipid packing identifies apoptotic thymocytes. Immunol. Lett. 36:1993;283-288.
17. Stillwell W., WassaIl S.R., Dumaual A.C., Ehringer W.D., Browning C.D., Jeskin L.G. Use of merocyanine (MC540) in quantifying lipid domains and packing in phospholipid vesicles and tumor cells. Biochim. Biophys. Acta. 1146:1993;136-144.
18. Foxall D.L., Cohen J.S., Mitchell J.B. Continuous perfusion of mammalian cells embedded in agarose gel threads. Exp. Cell Res. 154:1984;521-529.
19. Foxall D.L., Cohen J.S. NMR studies of perfused cells. J. Magn. Reson. 52:1983;346-349.
20. Callaghan R., Stafford A., Epand R.M. Increased accumulation of drugs in multidrug resistant cells by alteration of membrane biophysical properties. Biochim. Biophys. Acta. 1175:1993;277-282.
21. Emsley J., King S.L., Bergelson J.M., Liddington R.C. Crystal structure of the I domain from integrin alpha2beta1. J. Biol. Chem. 272:1997;28512-28517.
22. Kozar M.P., Krahmer M.T., Fox A., Larsson L., Allton J.H. Lunar dust: a negative control for biomarker analyses of extra-terrestrial samples? Geochim. Cosmochim. Acta. 65:2001;3307-3317.
23. Kaplan O., Jaroszewski J.W., Clarke R., Fairchild C.R., Schoenlein P., Goldenberg S., Gottesman M.M., Cohen J.S. The multidrug resistance phenotype: 31p nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. Cancer Res. 51:1991;1638-1644.
24. Kaplan O., van Zijl P.C.M., Cohen J.S. NMR studies of metabolism of cells and perfused organs. NMR Basic Principles and Progress. vol. 28:1992;3-52 Springer, Berlin.
25. Thomson S.W., Davis L.E., Kornfeld M., Hilgers R.D., Standefer J.C. Cisplatin neuropathy, clinical, electrophysiologic, morphology, and toxicologic studies. Cancer. 54:1984;1269-1275.
26. Mahaswari K.U., Ramachandran T., Rajaji D. Interaction of cisplatin with planar model membranes - Dose dependent change in electrical characteristics. Biochim. Biophys. Acta. 1463:2000;230-240.
27. 549 cells and their resistance to cisplatin. Int. J. Biochem. Cell Biol. 34:2002;1248-1255.
28. Burger K.N.J., Rutger W.H.M., Staffhorst M., Kruijff B.D. Interaction of the anti-cancer drug cisplatin with phosphadidylserine in intact and semi intact cells. Biochim. Biophys. Acta. 1419:1999;43-54.
29. Timmer-Bosscha H., Hospers G.A., Meijer C., Mulder N.H., Muskiet F.A., Martini I.A., Uges D.R., de Vries E.G. Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J. Natl. Cancer Inst. 81:1989;1069-1075.
30. Chauhan S.S., Liang X.-J., Su A.W., Pai-Panandiker A., Shen D.-W., Hanover J.A., Gottesman M.M. Reduced endocytosis and altered lysosome function in cisplatin resistant cell lines. Br. J. Cancer. 88:2003;1327-1334.
31. Liang X.-J., Shen D.-W., Garfield S., Gottesman M.M. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res. 63:2003;5909-5916.